(Q54755584)

English

Panobinostat clinical trial highlights the challenges towards an HIV cure.

scientific article

In more languages

edit

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

3 June 2018

http://europepmc.org/abstract/MED/26424118

title

Panobinostat clinical trial highlights the challenges towards an HIV cure. (English)

1 reference

stated in

Europe PubMed Central

3 June 2018

http://europepmc.org/abstract/MED/26424118

author name string

Clovis S Palmer

series ordinal

1

1 reference

stated in

Europe PubMed Central

3 June 2018

http://europepmc.org/abstract/MED/26424118

Suzanne M Crowe

series ordinal

2

1 reference

stated in

Europe PubMed Central

3 June 2018

http://europepmc.org/abstract/MED/26424118

publication date

24 November 2014

1 reference

stated in

Europe PubMed Central

3 June 2018

http://europepmc.org/abstract/MED/26424118

published in

The lancet. HIV

1 reference

stated in

Europe PubMed Central

3 June 2018

http://europepmc.org/abstract/MED/26424118

volume

1

1 reference

stated in

Europe PubMed Central

3 June 2018

http://europepmc.org/abstract/MED/26424118

issue

3

1 reference

stated in

Europe PubMed Central

3 June 2018

http://europepmc.org/abstract/MED/26424118

page(s)

e103

1 reference

stated in

Europe PubMed Central

3 June 2018

http://europepmc.org/abstract/MED/26424118

cites work

Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1016%2FS2352-3018%2814%2900009-5

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+ T cells to HIV by increasing the kinetics and efficiency of postentry viral events.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1016%2FS2352-3018%2814%2900009-5

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1016%2FS2352-3018%2814%2900009-5

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased glucose metabolic activity is associated with CD4+ T-cell activation and depletion during chronic HIV infection

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1016%2FS2352-3018%2814%2900009-5

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1016%2FS2352-3018%2814%2900009-5

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

DOI

10.1016/S2352-3018(14)00009-5

1 reference

stated in

Europe PubMed Central

3 June 2018

http://europepmc.org/abstract/MED/26424118

PubMed ID

26424118

1 reference

stated in

Europe PubMed Central

3 June 2018

http://europepmc.org/abstract/MED/26424118

(Q54755584)

Panobinostat clinical trial highlights the challenges towards an HIV cure.

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)